DNA vectors, transposons and transposases for eukaryotic genome modification
The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
1. A polynucleotide comprising a segment having a sequence at least 99% identical to SEQ ID NO: 866, wherein the segment comprises SEQ ID NO: 869 and either SEQ ID NO: 867 or 868, the segment effective to enhance expression of a gene incorporating the segment between a coding sequence and 3′ polyA sequence.
2. The polynucleotide of claim 1 , wherein the polynucleotide further comprises a segment encoding a selectable marker.
3. The polynucleotide of claim 2 , wherein the selectable marker is one of the following: glutamine synthase, dihydrofolate reductase, puromycin-N acetyl transferase, blasticidin-S deaminase, hygromycin phosphotransferase, aminoglycoside phosphotransferase, nourseothircin N-acetyl transferase, or a protein that binds to zeocin.
4. The polynucleotide of claim 2 , wherein the segment encoding the selectable marker is operably linked to a promoter which is at least 95% identical to a sequence selected from SEQ ID NOS: 937-948.
5. The polynucleotide of claim 1 , wherein the polynucleotide further comprises a eukaryotic promoter.
6. The polynucleotide of claim 5 , wherein the promoter is selected from one of the following: an EF1a promoter, a CMV promoter, an EEF2 promoter, an SV40 promoter, a PGK promoter, an actin promoter, an AOX promoter, a GAPDH promoter, an ILV5 promoter or an HSV-TK promoter.
7. The polynucleotide of claim 5 , wherein the promoter is at least 95% identical to a sequence selected from SEQ ID NO: 892-936.
8. The polynucleotide of claim 1 , wherein the polynucleotide further comprises an intron.
9. The polynucleotide of claim 8 , wherein the intron is selected from one of the following: an EF1a intron, an EEF2 intron, a CMV intron, an actin intron, a GAPDH intron, an SV40 intron.
10. The polynucleotide of claim 8 , wherein the intron is at least 95% identical to a sequence selected from SEQ ID NOS: 958-997.
11. The polynucleotide of claim 1 , wherein the polynucleotide further comprises a promoter and an intron that is heterologous to said promoter.
12. The polynucleotide of claim 1 , wherein the polynucleotide further comprises an IRES.
13. The polynucleotide of claim 12 , wherein the IRES is at least 95% identical to a sequence selected from SEQ ID NO: 1050-1094.
14. The polynucleotide of claim 1 , further comprising a sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 998-1049.
15. The polynucleotide of claim 1 , further comprising a sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 820-858.
16. The polynucleotide of claim 1 , further comprising a sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 751-819.
17. The polynucleotide of claim 1 , further comprising a sequence that is at least 90% identical to a sequence selected from SEQ ID NO: 719-749.
18. The polynucleotide of claim 1 , wherein the polynucleotide further comprises an insulator.
19. The polynucleotide of claim 18 , wherein the insulator is at least 95% identical to a sequence selected from one of SEQ ID NOS: 859-865.
20. An isolated cell whose genome comprises the polynucleotide of claim 1 operably linked to a sequence to be expressed.